ONCOLOGY NURSING SOCIETY
BOARD OF DIRECTORS
APPROVED MINUTES

Date: Tuesday, March 27, 2018
Place: Conference Call
Time: 6:00 p.m. to 8:00 PM EDT

Attendees: President, Susan Schneider; President-Elect, Laura Fennimore; Secretary, Barbara Holmes Gobel; Treasurer, Kay Harse; Directors-at-Large, Diane Barber, Eva Gallagher, Joni Watson, Maggie Smith, Julie Painter, Jean Rosiak; Chief Executive Officer, Brenda Nevidjon

Absent: none

Guest: Michele Galioto, Assistant Chief Clinical Officer; Barb Lubejko, Oncology Clinical Specialist; Lori Brown, Chief Experience Officer

Recorder(s): Jennifer DiVito

I. **Call to Order**
S. Schneider called the meeting to order at 6:01 pm EDT

II. **Welcome and Catch Up**
S. Schneider welcomed the Board members to the March conference call.

III. **Assignment of To-Do List and Timekeeper**
K. Harse has been assigned to capture the to-do list and J. Painter will be the timekeeper.
IV. Approval of Agenda including consent agenda and timeframes
M. Smith moved to approve the agenda including the consent agenda and timeframes as amended. The motion was adopted. The Chapter Charter renewal item now consists of 216.

V. Conflict of Interest
None noted.

VI. E-mail Vote
The February board meeting minutes were approved via email on 3/27/18.

ACTION AGENDA

VII. Scope and Standards
The update to the Oncology Nursing: Scope and Standards of Practice, which were last published in 2013, began in August 2017. The intent of this update is twofold: to ensure that the scope and standards are consistent with current oncology nursing practice and to prepare for submission to the American Nurses Association (ANA) for approval of specialty nursing scope of practice statement and acknowledgement of specialty nursing standards of practice. A team of two ONS Oncology Clinical Specialists (Barbara Lubejko, MS, RN and Laurl Matey, MSN, RN, CHPN®) and an ONS member (Barbara Wilson, MS, RN, AOCN®, ACNS-BC) with experience in developing standards of practice was convened to manage the work.

Once the first draft of the updated scope and standards document was completed, a public comment period was opened. An invitation was sent to all ONS members and ANA also shared the invitation with their community.

J. Watson moved to approve the Scope and Standards to the ANA for approval and acknowledgement. The motion was adopted.
VIII. ACS-CAN Clinical Trials Barriers work group recommendations
In May 2017, the ACS Cancer Action Network put together a workgroup to explore the current state of knowledge about barriers to clinical trials accrual. The workgroup included representatives from multiple professional, healthcare and patient advocacy organizations as well as clinical research organizations and pharmaceutical companies. The aim of the project was to change the landscape of clinical trial enrollment by identifying and tackling some of the persistent barriers to clinical trial enrollment. The intent was not to repeat previous reports and research, but to describe the landscape of challenges to enrollment along with existing efforts to overcome these challenges. In addition, consensus recommendations for programmatic and policy changes have been developed. 
J. Rosiak moved to endorse the Recommendations for Overcoming Barriers to Patient Enrollment in Therapeutic Clinical Trials for Cancer. The motion was adopted.

VIX. Approval of modifications to the LDC Charter
The major revisions to the charter include the addition of one joint meeting with the LDC and the ONS Board annually, the LDC Chair will be invited to participate as a member of the Presidents Council, and the LDC Chair will be invited to participate in Board calls and meetings as necessary. 
K. Harse moved to approve the revisions to the Leadership Development Committee charter as outlined. 
The motion was adopted. 
Moving forward, the incoming President will work with the ONS Board to develop goals for the Leadership Development Committee.

X. Leadership Development Committee member selection
The ONS Board will need to replace two members of the Leadership Development Committee when their term ends in May 2018. The ONS Board reviewed the current needs for the Committee and discussed ten potential members for the Leadership Development Committee. A survey will be sent to the Board to rank their top four, based on those results the President and CEO will reach out to the top two candidates to assess their interest to serve.
XI. Chapter Charter renewals
Annually, the ONS Board renews the charters for the ONS Chapters based on meeting their re-chartering requirements.
J. Rosiak moved to renew the charters of the 216 chapters, designated on the report, who met all re-chartering requirements. The motion was adopted.
K. Harse moved to approve the request to disband the CURE New Jersey and Wheatland (KS) Chapters. The motion was adopted.

XII. Position review
K. Harse moved to approve the ONS position statement titled Role of the Oncology Nurse Navigator Throughout the Cancer Trajectory with recommended edits. The motion was adopted.
D. Barber moved to endorse the ASCO position statement titled Alcohol and Cancer: A Statement of the American Society of Clinical Oncology. The motion was adopted.
J. Painter moved to endorse the ASCO position statement titled American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations. The motion was adopted.
K. Harse moved to endorse the HOPA position statement titled Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. The motion was adopted.

XIII. Wrap-Up
At the end of the conference call, J. DiVito will be distributing an election poll to vote on the incoming Treasurer.
The ONS Board discussed the ONS Foundation Match to Inspire Challenge which is an opportunity to secure donations prior to Congress to encourage Congress participants to donate while onsite. The ONS Foundation is working to establish 10 Team, by committing to a team you are encouraged to donate $10,000 to the Foundation prior to Congress.
The consensus is the ONS Board will establish a “team” to assist in the fundraising efforts of the ONS Foundation.

XIV. Adjournment
The meeting was adjourned by President, S. Schneider at 8:01 pm EDT.

Respectfully submitted,

Barbara Holmes Gobel, MS, RN, AOCN, FAAN
Secretary, Oncology Nursing Society